ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

An Integrative Pharmacology Model for Decoding the Underlying Therapeutic Mechanisms of Ermiao Powder for Rheumatoid Arthritis

Wu, Jie; Wang, Kexin; Liu, Qinwen; Li, Yi; Huang, Yingying; Liu, Yujie; Cai, Jieqi; Yin, Chuanhui; Li, Xiaowei; Yu, Hailang; Meng, Wei; Wang, Handuo; Lu, Aiping*; Li, Yazi; Guan, Daogang*南方医科大学
Frontiers in Pharmacology2022-2-23DOI: 10.3389/fphar.2022.801350
6被引10阅读
引用收藏
分享

摘要

As a systemic inflammatory arthritis disease, rheumatoid arthritis (RA) is complex and hereditary. Traditional Chinese medicine (TCM) has evident advantages in treating complex diseases, and a variety of TCM formulas have been reported that have effective treatment on RA. Clinical and pharmacological studies showed that Ermiao Powder, which consists of Phellodendron amurense Rupr. (PAR) and Atractylodes lancea (Thunb.) DC. (ALD), can be used in the treatment of RA. Currently, most studies focus on the anti-inflammatory mechanism of PAR and ALD and are less focused on their coordinated molecular mechanism. In this research, we established an integrative pharmacological strategy to explore the coordinated molecular mechanism of the two herbs of Ermiao Powder in treating RA. To explore the potential coordinated mechanism of PAR and ALD, we firstly developed a novel mathematical model to calculate the contribution score of 126 active components and 85 active components, which contributed 90% of the total contribution scores that were retained to construct the coordinated functional space. Then, the knapsack algorithm was applied to identify the core coordinated functional components from the 85 active components. Finally, we obtained the potential coordinated functional components group (CFCG) with 37 components, including wogonin, paeonol, ethyl caffeate, and magnoflorine. Also, functional enrichment analysis was performed on the targets of CFCG to explore the potential coordinated molecular mechanisms of PAR and ALD. The results indicated that the CFCG could treat RA by coordinated targeting to the genes involved in immunity and inflammation-related signal pathways, such as phosphatidylinositol 3-kinase/protein kinase B signaling pathway, mitogen-activated protein kinase signaling pathway, tumor necrosis factor signaling pathway, and nuclear factor-kappa B signaling pathway. The docking and in vitro experiments were used to predict the affinity and validate the effect of CFCG and further confirm the reliability of our method. Our integrative pharmacological strategy, including CFCG identification and verification, can provide the methodological references for exploring the coordinated mechanism of TCM in treating complex diseases and contribute to improving our understanding of the coordinated mechanism.

学科与关键词

关键词
rheumatoid arthritis (RA)traditional Chinese medicine (TCM)Ermiao Powder (EMP)coordinated functional components group (CFCG)coordinated molecular mechanisms
相关
加载中…
  • An integrative pharmacology model for decoding the underlying Therapeutic Mechanisms of Ermiao Powder for Rheumatoid arthritis (vol 13, 801350, 2022)
    Wu, Jie; Wang, Kexin; Liu, Qinwen; Li, Yi; Huang, Yingying; Liu, Yujie; Cai, Jieqi; Yin, Chuanhui; Li, Xiaowei; Yu, Hailang; Meng, Wei; Wang, Handuo; Lu, Aiping*; Li, Yazi; Guan, Daogang*Frontiers in Pharmacology, 2023, 14: 1302388.
  • System pharmacology analysis to decipher the effect and mechanism of active ingredients combination from herb couple on rheumatoid arthritis in rats
    Wu, Shan-Shan; Xu, Xi-Xi; Shi, Yuan-Yuan; Chen, Yi; Li, Ying-Qi; Jiang, Si-Qi; Wang, Ting*; Li, Ping*; Li, Fei*Journal of Ethnopharmacology, 2022, 288: 114969.被引 8
  • Mechanism investigation of Duhuo Jisheng pill against rheumatoid arthritis based on a strategy for the integration of network pharmacology, molecular docking and in vivo experimental verification
    Xin, Ping; Xu, Xiaoyun; Zhang, Huaxi; Hu, Yuezhou; Deng, Chengjie; Sun, Shiqin; Liu, Shuang; Zhou, Xuegang*; Ma, Hongxing*; Li, Xiaoliang*PHARMACEUTICAL BIOLOGY, 2023, 61(1): 1431-1445.被引 1
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Pharmacology
发表日期
2022-02-23
卷期
第 13 卷
页码
801350
DOI
10.3389/fphar.2022.801350
语言
ENGLISH
期刊等级
2区
成果收录
SCIE
资助标注
Startup fund from the Southern Medical University [G820282016]; Natural Science Foundation Council of China [31501080, 32070676, 31900886]; Natural Science Foundation of Guangdong Province [2021A1515010737]; Hong Kong Baptist University Strategic Development Fund [SDF13-1209-P01, 2018A030313392, SDF19-0402-P02]; Hong Kong Baptist University Interdisciplinary Research Matching Scheme [RC/IRCs/17-18/04]; 2020 Guangdong Provincial Science and Technology Innovation Strategy Special Fund [2020B1212030006]; Guangzhou Basic and Applied Basic Research Foundation [202102020550]; Guangdong Basic and Applied Basic Research Foundation [SDF15-0324-P02(b)]; [SDF15-0324-P02]

作者

  • W

    Wu, Jie (第一作者)

    southern med univ

  • W

    Wang, Kexin

    southern med univ

查看全部 15 位作者收起作者
  • L

    Liu, Qinwen

    southern med univ

  • L

    Li, Yi

  • H

    Huang, Yingying

    southern med univ

  • L

    Liu, Yujie

    southern med univ

  • C

    Cai, Jieqi

    southern med univ

  • Y

    Yin, Chuanhui

    southern med univ

  • L

    Li, Xiaowei

    southern med univ

  • Y

    Yu, Hailang

    southern med univ

  • M

    Meng, Wei

    southern med univ

  • W

    Wang, Handuo

    southern med univ

  • L

    Lu, Aiping (通讯)

    hong kong baptist univ

  • L

    Li, Yazi

  • G

    Guan, Daogang (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417